What is Bilateral Thygeson's Disease?
Bilateral Thygeson's superficial punctate keratitis (TSPK) is a chronic, recurrent corneal epithelial disease characterized by multiple gray-white intraepithelial opacities in the central cornea of both eyes, causing photophobia, blurred vision, tearing, and eye irritation, with a waxing-and-waning course that can persist for years to decades 1, 2.
Clinical Characteristics
TSPK presents with distinctive features that help differentiate it from other corneal conditions:
- Bilateral involvement in the vast majority of cases (84% at presentation), though it may initially appear unilateral or be asymmetric 3, 4
- Multiple discrete gray-white epithelial lesions concentrated in the central cornea with minimal to no conjunctival injection 1, 5
- Relatively preserved vision - most patients (79%) maintain visual acuity of 20/30 or better at presentation, though symptoms may be disproportionate to clinical findings 3
- Chronic relapsing-remitting course averaging 11.1 years in duration, with some cases persisting for decades 3
Pathophysiology and Etiology
The exact cause remains unknown, though several mechanisms have been proposed 2:
- Immune-mediated process - correlation with HLA-DR3 antigen suggests immunogenic involvement 5
- Langerhans cell proliferation in the corneal epithelium positively correlates with disease exacerbations 1
- Post-viral immune response has been hypothesized, though PCR studies consistently fail to detect active viral infection during symptomatic episodes 1
Importantly, TSPK does not respond to antiviral or antibacterial treatment, supporting its non-infectious nature 1.
Clinical Pitfalls
A critical caveat: TSPK can rarely present with dendritic corneal lesions mimicking herpetic keratitis 6. In one documented case, a patient initially diagnosed with herpes simplex keratitis based on dendritic lesions later developed classic bilateral TSPK. This highlights that TSPK should remain in the differential diagnosis even when dendritic patterns are present, particularly if the condition recurs after apparent resolution with antiviral therapy 6.
Treatment Approach
Topical corticosteroids remain the mainstay of treatment, with 97.5% of patients requiring steroids at some point in their disease course 3. However, the chronic nature necessitates steroid-sparing strategies:
First-line Management
- Fluorometholone 0.1% shows good response in 80% of pediatric cases and is widely used in adults 4
- Artificial tears for mild symptoms or as adjunctive therapy 5, 3
Steroid-sparing Alternatives
- Topical cyclosporine A 0.05-0.1% significantly reduces total steroid exposure and can maintain remission 6, 2, 4
- Topical tacrolimus has emerged as a promising immunomodulatory alternative 2, 5
- Extended-wear soft contact lenses can provide symptomatic relief in select cases 3
Refractory Cases
- Photorefractive keratectomy (PRK) or phototherapeutic keratectomy (PTK) reserved for cases unresponsive to medical management 2
Taper Strategy
Slow steroid taper every 4-6 weeks is essential to prevent recurrences, with frequency increased during flares 4. Long-term monitoring for steroid-induced complications (glaucoma, cataracts) is mandatory.
Diagnostic Considerations
TSPK should be considered a diagnosis of exclusion in bilateral superficial punctate keratopathy of long duration 5. When clinical response to steroids is poor or atypical features are present, corneal scraping may be necessary to exclude infectious causes or alternative diagnoses such as TGFBI-related stromal dystrophies 4.
The disease affects all age groups, with mean presentation age of 28.7 years in adults 3, though pediatric cases are well-documented 4. Recent case reports have linked TSPK onset to COVID-19 vaccination, suggesting potential immune triggers 7.